The six-minute walk test (6MWT) is a non-invasive test used to assess cardiopulmonary performance. The aim of this study was to evaluate the performance of 6MWT in predicting pulmonary artery hypertension (PAH) and interstitial lung disease in patients with systemic sclerosis (SSc) and cardiopulmonary symptoms. Sixty-three patients with SSc who had dyspnea, cough, chest pain and syncope underwent 6MWT, high-resolution computed tomography (HRCT), spirometry, body plethysmography and single breath carbon monoxide diffusion measurement. There were no significant differences in mean 6MWD between patients with diffuse SSc compared with limited disease, patients with no parenchymal involvement compared with patients with parenchymal involvement &...
Objective: To assess the reproducibility and the utility of the 6-minute walk test (6MWT) in systemi...
Introduction: Patients with mean pulmonary artery pressures (mPAP) of 21 to 24 mm Hg have a so-calle...
Introduction: Sarcoidosis associated pulmonary hypertension (SAPH) is a leading contributor to sarco...
International audienceObjectives Despite the wide use of the 6 min walk distance (6MWD), no study ha...
Objective: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading...
OBJECTIVES: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leadin...
Background: Pulmonary involvement is the leading cause of systemic sclerosis (SSc)-related deaths. A...
Pulmonary involvement is the leading cause of systemic sclerosis (SSc)-related deaths. A simple test...
International audienceBACKGROUND: There is an ongoing debate regarding the relevance of the 6-minute...
The 6-minute walk test (6MWT) is a standardised, feasible and reliable measure of sub-maximal exerci...
Objective. To identify factors indicating exercise-induced oxygen desaturation during the 6-minute w...
Background The six minute walking test (6MWT) is a standardised measure of submaximal exercise capac...
Background: Six minute walk test (6MWT) is a sub-maximal exercise test, used as a clinical indicator...
Orientador: Ilma Aparecida PaschoalTese (doutorado) - Universidade Estadual de Campinas, Faculdade d...
Background The 6-minute walk test (6MWT) is a commonly used to evaluate exercise capacity in patient...
Objective: To assess the reproducibility and the utility of the 6-minute walk test (6MWT) in systemi...
Introduction: Patients with mean pulmonary artery pressures (mPAP) of 21 to 24 mm Hg have a so-calle...
Introduction: Sarcoidosis associated pulmonary hypertension (SAPH) is a leading contributor to sarco...
International audienceObjectives Despite the wide use of the 6 min walk distance (6MWD), no study ha...
Objective: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading...
OBJECTIVES: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leadin...
Background: Pulmonary involvement is the leading cause of systemic sclerosis (SSc)-related deaths. A...
Pulmonary involvement is the leading cause of systemic sclerosis (SSc)-related deaths. A simple test...
International audienceBACKGROUND: There is an ongoing debate regarding the relevance of the 6-minute...
The 6-minute walk test (6MWT) is a standardised, feasible and reliable measure of sub-maximal exerci...
Objective. To identify factors indicating exercise-induced oxygen desaturation during the 6-minute w...
Background The six minute walking test (6MWT) is a standardised measure of submaximal exercise capac...
Background: Six minute walk test (6MWT) is a sub-maximal exercise test, used as a clinical indicator...
Orientador: Ilma Aparecida PaschoalTese (doutorado) - Universidade Estadual de Campinas, Faculdade d...
Background The 6-minute walk test (6MWT) is a commonly used to evaluate exercise capacity in patient...
Objective: To assess the reproducibility and the utility of the 6-minute walk test (6MWT) in systemi...
Introduction: Patients with mean pulmonary artery pressures (mPAP) of 21 to 24 mm Hg have a so-calle...
Introduction: Sarcoidosis associated pulmonary hypertension (SAPH) is a leading contributor to sarco...